Latest Regulatory Approvals News

Alligator Energy Limited has made significant strides in its uranium exploration and development projects, securing critical regulatory approvals and advancing field operations while maintaining a robust cash position. The company’s strategic investments and ongoing drilling programs position it well amid a strengthening uranium market.

Boab Metals has inked a A$10 million deal to acquire the DeGrussa Processing Plant from Sandfire Resources, significantly derisking and reducing upfront capital costs for its Sorby Hills Project. Completion hinges on a final investment decision expected in the second half of 2025.

Argent BioPharma reports significant operational savings through manufacturing outsourcing, encouraging Phase IIb results for CimetrA®, and key regulatory approvals for cannabinoid therapies in Germany.

EV Resources Limited advances its position in the critical antimony market with a 70% stake acquisition in Mexico’s Los Lirios project and full ownership of Utah’s historic Coyote Creek claims, setting the stage for exploration and development.

Alterity Therapeutics reports compelling Phase 2 clinical trial results for ATH434 in Multiple System Atrophy, alongside a significant capital raise strengthening its financial position for upcoming regulatory milestones.

CZR Resources has terminated its prior deal with Miracle Iron and endorsed a superior A$75 million cash offer from the Rio Tinto-led Robe River Iron Associates JV for its Robe Mesa Project. The company retains promising gold and titanium-vanadium assets while preparing for shareholder approval.

Global Lithium Resources has resumed its Definitive Feasibility Study at the Manna Lithium Project, focusing on cost optimization and project economics, while advancing heritage and native title agreements. The company also reported significant board changes and a robust cash position heading into 2025.

PEXA has achieved a crucial regulatory milestone with FCA approval to operate as an Authorised Payment Institution in the UK, paving the way for its Sale & Purchase product launch later this year.

Althea Group Holdings reported $5.02 million in Q3 FY25 receipts, driven by strong growth at Peak Canada and the launch of Peak USA, while its pharmaceutical cannabis division faces steep revenue declines prompting strategic review.

Inca Minerals has secured over 94% ownership of Stunalara Metals, gaining access to the promising Hurricane Project in North Queensland. With an oversubscribed $1.1 million capital raise, maiden drilling is set to begin in Q2 2025, targeting high-grade gold and antimony mineralisation.

Optiscan Imaging Ltd has revealed its next-generation InForm™ pathology imaging device and strengthened its executive team, while reporting a robust cash position supported by a $1.775 million R&D tax refund for the quarter ended 31 March 2025.

Orthocell has secured Health Canada approval for its nerve repair product Remplir™, adding the US$75 million Canadian market and expanding its total addressable market to US$1.8 billion. The company plans to appoint local distributors and expects first sales in H2 2025.